Statement of Work

Proposal Number: MTEC-20-09-COVID19-050

Organization: Centivax

Title: (b) (4) to COVID-19 for Immediate Clinical Use ACURO and/or HRPO approval needed: ACURO Approvals Needed. HRPO Approval Needed if Option Year

Funded.

EGS #: MT20009.050

Programmatic Relevance: Pandemic COVID-19 causes severe disease in 10-20% of the infected, requiring long hospitalization and causing a 10% mortality rate for those hospitalized. High virus transmissibility results in rapid outbreaks and exhaustion of hospital facilities and infection of staff. Currently, there are no FDA-approved vaccines or treatments for COVID-19. Although vaccines are under development, they cannot be used to treat the already sick and will not be ready until 2021. Thus, a therapeutic capable of immediate action and able to be used prophylactically to protect healthcare workers, the immunocompromised, the elderly, as well as infected individuals is critically needed.

Centivax (b) (4)

Antibodies have precedent of being extremely effective in combating viral outbreaks. Specifically, antibody therapeutics for Ebola transformed survival from 50% to over 94% for those who received the treatment early. Additionally, antibody therapeutics for rabies transform survival from 0% to nearly 100%. Antibody therapeutics are given to infants for RSV and as antivirals for HIV. Therefore, a SARS-CoV-2 antibody therapeutic will be effective where a vaccine is not. Reducing the COVID-19 mortality rate and decreasing recovery time in the hospital has the potential to significantly impact the crisis.

Non-clinical Data/Technical Abstract: Centivax (b) (4)

January 27th to March 30th, Centivax (b) (4)


(b) (4)

These parental antibodies were valuable in that they already had been well studied: they have been established to bind, neutralize, and protect against the SARS coronavirus. (b) (4)

(b) (4)

(b) (4)





Manufacturing feasibility (b) (4)

(b) (4)




Figure 2. Centivax (b) (4)

The scope of our effort is to demonstrate Centivax's (b) (4)
(b) (4)

Project Objectives: Centivax's therapeutic is a *complete solution to the requirements presented in this RPP*, and *provides a GO/NO GO decision* for continued Phase I/II clinical studies.

Objective 1: (b) (4)
Objective 2: (b) (4)
Objective 3: (b) (4)
Objective 4: (b) (4)
Objective 5: (b) (4)
Objective 6a: (b) (4)
Objective 6b: (b) (4)

Table 2: Anticipated Outcomes (Does not include Labor Costs)

product to enter a Phase I/II clinical trials for the treatment of COVID-19.

Objective	Task	Deliverable	Time
1	(b) (4)	(b) (4)	2-3 weeks
2	(b) (4)	(b) (4)	2-4 weeks

3	(b) (4)	(b) (4)	2-4 weeks
4	(b) (4)	(b) (4)	2 weeks
5	(b) (4)	(<u>b</u>) (4)	10 weeks
Option 6a	(b) (4)	(b) (4)	8 Weeks
Option 6b	(b) (4)	(b) (4)	3-9 Months
		(b) (4)	

Milestone Payment schedule

Based on the information provided by MTEC, CentiVax proposes to apply the following resources charged at the prices indicated below to meet the project objectives. Should CentiVax's needs change, this will be updated accordingly in a subsequent amendment to this Statement of Work.

Milestone Payment Schedule					
MTEC Milestone Number	Objective Number	Task	Due Date	Government Funds	Total Funding
1	N/A	Initiation of the program	7/5/20	\$(b) (4)	\$(b) (4)
2	1	Submission for ACURO approvals	TBD	(b) (4)	(b) (4)
3	1	Receipt of ACURO Approvals	TBD	(b) (4)	(b) (4)
4	1	(h) (4) p) (4)	7/5/20	\$(b) (4)	\$ <mark>(b) (4)</mark>
5	2	(b) (4)	7/20/20	\$(b) (4)	\$(b) (4)
6	3	(b) (4)	7/5/20	\$ <mark>(b) (4)</mark>	\$ <mark>(b) (4)</mark>
7	4	(b) (4)	7/30/20	\$ <mark>(b) (4)</mark>	\$(b) (4)

8	N/A	Quarterly Report 1 (April-June Technical and Business Reports)	7/25/20	(b) (4)	(b) (4)
9	5	Regulatory Toxicology Study (CRL)	8/30/20	\$(b) (4)	\$ <mark>(b) (4)</mark>
10	N/A	Annual Technical Report, Final Technical Report, and Final Business Status Report	1/25/21	(b) (4)	(b) (4)
		Total		\$ <mark>(b) (4)</mark>	\$1,206,824

DATA RIGHTS ASSERTIONS

Government Purpose Data Rights.